Revenue Breakdown
Composition ()
No data
Revenue Streams
Profitability & Margins
Evaluating the bottom line, Kalvista Pharmaceuticals Inc maintains a gross margin of 91.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -336.33%, while the net margin is -361.39%. These profitability ratios, combined with a Return on Equity (ROE) of -343.93%, provide a clear picture of how effectively KALV converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, KALV competes directly with industry leaders such as MPLT and ABUS. With a market capitalization of $801.92M, it holds a significant position in the sector. When comparing efficiency, KALV's gross margin of 91.00% stands against MPLT's N/A and ABUS's 100.00%. Such benchmarking helps identify whether Kalvista Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.
